Document is current

Documents that mention this clinical trial

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
https://doi.org/10.1136/jitc-2021-002374

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
https://doi.org/10.1136/jitc-2023-007386

Circulating immune cell landscape in patients who had mild ischaemic stroke
https://doi.org/10.1136/svn-2021-001224

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

840 A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression
https://doi.org/10.1136/jitc-2021-sitc2021.840

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
https://doi.org/10.1136/jitc-2019-000450

727 Resistance to enzalutamide and abiraterone drives tumor phenotypic plasticity and resistance to immune-mediated cytotoxicity
https://doi.org/10.1136/jitc-2021-sitc2021.727

710 Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist)
https://doi.org/10.1136/jitc-2021-sitc2021.710

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
https://doi.org/10.1136/jitc-2020-002258

Documents that mention this clinical trial

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Documents that mention this clinical trial

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
https://doi.org/10.1136/jitc-2021-003302

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
https://doi.org/10.1136/jitc-2020-001246

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404

296 Immune correlates of clinical response to Avelumab in patients with advanced thymic epithelial tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0296

Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255

34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1

Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
https://doi.org/10.1016/j.ygyno.2015.02.019

Efficacy and immune-related adverse event associations in avelumab-treated patients
https://doi.org/10.1136/jitc-2020-001427

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
https://doi.org/10.1136/jitc-2021-002998

540 Baseline mTOR transcriptional signatures in CD8 T cells are associated with immune-related adverse events but not anti-tumor responses in patients receiving immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2021-sitc2021.540

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
https://doi.org/10.1136/annrheumdis-2018-213777

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study
https://doi.org/10.1136/jitc-2020-001064

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552

Documents that mention this clinical trial

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Documents that mention this clinical trial

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Documents that mention this clinical trial

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
https://doi.org/10.1136/jitc-2021-003238

Documents that mention this clinical trial

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
https://doi.org/10.1136/jitc-2021-003238

Documents that mention this clinical trial

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Documents that mention this clinical trial

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Documents that mention this clinical trial

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

Documents that mention this clinical trial

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378